Drowsiness Latest Advances

First orexin agonists address root cause of narcolepsy.

Journal: Nature biotechnology

Published: April 07, 2026

Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma.

Journal: BMJ case reports

Published: April 06, 2026

SleepJEPA: Learning the latent world of sleep with at-home sleep data to estimate disease risk.

Journal: medRxiv : the preprint server for health sciences

Published: April 03, 2026

The impact of antigen presentation on BBB disruption and neuroinflammation.

Journal: Physiology (Bethesda, Md.)

Published: March 31, 2026

Anti-Ma2 Encephalitis as a Treatable Cause of Narcolepsy Type 1: A Case Report.

Journal: The American journal of case reports

Published: March 28, 2026

The GBA1 p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Journal: medRxiv : the preprint server for health sciences

Published: March 27, 2026

Early Diagnosis of Nieman-Pick Disease Type C and Rapid Response of Gelastic Cataplexy to Treatment With N-Acetyl-L-Leucine: A Case Report.

Journal: The American journal of case reports

Published: March 19, 2026

Therapeutic Use of Melatonin for Gastrointestinal Motility and Hypersomnolence in a Patient With Pineal Cyst Pathology.

Journal: The American journal of case reports

Published: March 18, 2026

Therapeutic potential of histamine N-methyltransferase inhibition for the treatment of hypersomnia

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: March 01, 2026

Clinical approaches to hypersomnolence complaints in psychiatry: A narrative review.

Journal: L'Encephale

Published: February 27, 2026

Rare-variant burden across lysosomal genes implicates sialylation and ganglioside metabolism in Parkinson's disease.

Journal: medRxiv : the preprint server for health sciences

Published: February 27, 2026

Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 Drug evaluation.

Journal: Expert opinion on investigational drugs

Published: February 23, 2026

Drowsiness Latest Advances

Find the Latest Research About Drowsiness

First orexin agonists address root cause of narcolepsy.

First orexin agonists address root cause of narcolepsy.

Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma.

Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma.

SleepJEPA: Learning the latent world of sleep with at-home sleep data to estimate disease risk.

SleepJEPA: Learning the latent world of sleep with at-home sleep data to estimate disease risk.

The impact of antigen presentation on BBB disruption and neuroinflammation.

The impact of antigen presentation on BBB disruption and neuroinflammation.

Anti-Ma2 Encephalitis as a Treatable Cause of Narcolepsy Type 1: A Case Report.

Anti-Ma2 Encephalitis as a Treatable Cause of Narcolepsy Type 1: A Case Report.

The GBA1 p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

The GBA1 p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Early Diagnosis of Nieman-Pick Disease Type C and Rapid Response of Gelastic Cataplexy to Treatment With N-Acetyl-L-Leucine: A Case Report.

Early Diagnosis of Nieman-Pick Disease Type C and Rapid Response of Gelastic Cataplexy to Treatment With N-Acetyl-L-Leucine: A Case Report.

Therapeutic Use of Melatonin for Gastrointestinal Motility and Hypersomnolence in a Patient With Pineal Cyst Pathology.

Therapeutic Use of Melatonin for Gastrointestinal Motility and Hypersomnolence in a Patient With Pineal Cyst Pathology.

Therapeutic potential of histamine N-methyltransferase inhibition for the treatment of hypersomnia

Therapeutic potential of histamine N-methyltransferase inhibition for the treatment of hypersomnia

Clinical approaches to hypersomnolence complaints in psychiatry: A narrative review.

Clinical approaches to hypersomnolence complaints in psychiatry: A narrative review.

Rare-variant burden across lysosomal genes implicates sialylation and ganglioside metabolism in Parkinson's disease.

Rare-variant burden across lysosomal genes implicates sialylation and ganglioside metabolism in Parkinson's disease.

Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 Drug evaluation.

Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 Drug evaluation.